The Medicare Prescription Drug Inflation Rebate Program will lower coinsurance for Medicare Part B beneficiaries for certain drugs, with savings between $2 and $390 per average dose starting April 1.

Recent survey findings underscore that the vast majority of physicians believe prior authorization has a negative impact on patient care. In fact, some specialists think it leads to worse outcomes.

The annual list, now in its 17th year, was designed to celebrate companies that make ethical business practices a high priority. 

For the first time, Medicare will have the ability to negotiate prices of certain medications. These negotiations will focus on key questions such as the drug's benefits, the extent to which it fulfills an unmet medical need and its impact on Medicare beneficiaries.

The Medicare Payment Advisory Commission (MedPAC) wants to tie physician payments to inflation. Healthcare groups say it doesn't go far enough

A significant portion of U.S. adults have some past-due medical debt, according to a recent study from the Urban Institute, and the majority of those with debt owe non-profit hospitals.

According to the complaint, Rite Aid allegedly filled “at least” hundreds of thousands of unlawful prescriptions for controlled substances that lacked legitimate medical purpose, were not for a medically accepted indication or were not issued in the usual course of professional practice.

A new Alzheimer’s disease drug, Leqembi (lecanemab), will be covered by the Veterans Affairs for some patients, making the VA the first insurer to cover the drug.